[2] A Quiet but Important FDA Move On April 30, 2026, the FDA announced a proposal that did not generate much mainstream news coverage
Personalized strategies to enhance your success with GLP-1 therapy
Adding glucagon activity is counter-intuitive, because glucagon raises blood sugar
However, as newer, more powerful drugs enter the market, it will be essential to continue assessing their potential benefits and safety. Additional research would be prudent, according to Pannel, who hopes that further studies will explore the mechanisms behind the reduction in food noise. She anticipates that this line of study could result in more effective treatments for those with restrictive-type eating disorders. The future of GLP-1s in mental health care is promising, especially in treating eating disorders, improving obesity-related mental health and potentially addressing mood disorders and neurodegenerative diseases such as Alzheimers disease, Pannel said
What came next was learning how to build habits that could support long-term health
Key points The incretin hormone glucagon-like peptide 1 (GLP1) promotes satiety and potentiates insulin release and suppression of glucagon release in response to the ingestion of nutrients
